- Home
- XAIR vs PMN Comparison
XAIR vs PMN Comparison
Compare XAIR & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- PMN
- Stock Information
- Founded
- XAIR 2011
- PMN 2004
- Country
- XAIR United States
- PMN Canada
- Employees
- XAIR N/A
- PMN N/A
- Industry
- XAIR Medical/Dental Instruments
- PMN Pharmaceuticals and Biotechnology
- Sector
- XAIR Health Care
- PMN Health Care
- Exchange
- XAIR Nasdaq
- PMN Nasdaq
- Market Cap
- XAIR 17.0M
- PMN 16.0M
- IPO Year
- XAIR N/A
- PMN N/A
- Fundamental
- Price
- XAIR $2.25
- PMN $0.54
- Analyst Decision
- XAIR Strong Buy
- PMN Strong Buy
- Analyst Count
- XAIR 1
- PMN 3
- Target Price
- XAIR $11.00
- PMN $4.33
- AVG Volume (30 Days)
- XAIR 190.1K
- PMN 835.7K
- Earning Date
- XAIR 08-12-2025
- PMN 08-13-2025
- Dividend Yield
- XAIR N/A
- PMN N/A
- EPS Growth
- XAIR N/A
- PMN N/A
- EPS
- XAIR N/A
- PMN N/A
- Revenue
- XAIR $4,782,000.00
- PMN N/A
- Revenue This Year
- XAIR $266.61
- PMN N/A
- Revenue Next Year
- XAIR $140.76
- PMN N/A
- P/E Ratio
- XAIR N/A
- PMN N/A
- Revenue Growth
- XAIR 168.20
- PMN N/A
- 52 Week Low
- XAIR $2.02
- PMN $0.38
- 52 Week High
- XAIR $13.52
- PMN $1.59
- Technical
- Relative Strength Index (RSI)
- XAIR 35.48
- PMN 42.86
- Support Level
- XAIR $2.02
- PMN $0.51
- Resistance Level
- XAIR $2.42
- PMN $0.73
- Average True Range (ATR)
- XAIR 0.20
- PMN 0.07
- MACD
- XAIR -0.04
- PMN -0.02
- Stochastic Oscillator
- XAIR 17.97
- PMN 11.26
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.